Olanzapine and Appetite decreased - a phase IV clinical study of FDA data
Appetite decreased is found among people who take Olanzapine, especially for people who are female, 60+ old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Olanzapine and have Appetite decreased. It is created by eHealthMe based on reports of 47,890 people who have side effects when taking Olanzapine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
47,890 people reported to have side effects when taking Olanzapine.
Among them, 576 people (1.2%) have Appetite decreased.
What is Olanzapine?
Olanzapine has active ingredients of olanzapine. It is often used in bipolar disorder. eHealthMe is studying from 48,451 Olanzapine users for its effectiveness, alternative drugs and more.
What is Appetite decreased?
Appetite decreased (decreased appetite occurs when you have a reduced desire to eat) is found to be associated with 4,090 drugs and 4,080 conditions by eHealthMe.
Number of Olanzapine and Appetite decreased reports submitted per year:
Time on Olanzapine when people have Appetite decreased *:
Gender of people who have Appetite decreased when taking Olanzapine*:
Age of people who have Appetite decreased when taking Olanzapine *:
Common drugs people take besides Olanzapine *:
Common side effects people have besides Appetite decreased *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Olanzapine and have Appetite decreased?Check whether Appetite decreased is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
- Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .
Alternative drugs to, pros and cons of Olanzapine:
- Olanzapine (48,451 reports)
Appetite decreased treatments and more:
- Appetite decreased (201,416 reports)
COVID vaccines that are related to Appetite decreased:
- Appetite decreased in Moderna COVID Vaccine
- Appetite decreased in Pfizer BioNTech Covid Vaccine
- Appetite decreased in Johnson and Johnson Covid Vaccine
How severe was Appetite decreased and when was it recovered:
Expand to all the drugs that have ingredients of olanzapine:
- Appetite decreased and drugs with ingredients of olanzapine (1,092 reports)
Common drugs associated with Appetite decreased:
All the drugs that are associated with Appetite decreased:
- Appetite decreased (4,090 drugs)
Common conditions associated with Appetite decreased:
All the conditions that are associated with Appetite decreased:
- Appetite decreased (4,080 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on olanzapine (the active ingredients of Olanzapine) and Olanzapine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.